Clinics begin adopting Genetic Technologies risk test

LabPulse.com staff writers
Jun 30, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400

Genetic Technologies said Friday it has started implementing its geneType Risk Assessment Test at 16 medical practices across the Australian east coast.

The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.

It added that its geneType Hub strategy focuses on establishing centers of excellence and the routine use of geneType Risk Assessment Tests in clinics for appropriate patients.

Latest in Coronary Artery Disease
Artery Heart 3 D Social
Boston Scientific gets FDA approval for drug-coated balloon catheter
March 4, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Heart Attack Disease 3 D Social(1)
Elevated lipoprotein(a) predicts recurrent heart disease in seniors
June 13, 2023
Heart Attack Disease 3 D Social
RNA biomarkers may help confirm heart disease, study finds
March 30, 2023
Related Stories
Sequencing Dna Rna Social
Collaboration
Genetic Technologies, Qiagen forming strategic alliance
2019 10 25 22 16 3822 Lab Hb A1c Diabetes 400
Diagnostic Technologies
Precision Diabetes, DxGen to launch diabetes analyzer
2022 06 21 20 59 0869 Business Agreement 400
Collaboration
Genetic Technologies completes AffinityDNA asset purchase
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Coronary Artery Disease
Boston Scientific gets FDA approval for drug-coated balloon catheter
By LabPulse.com staff writers
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Agent drug-coated balloon, a paclitaxel-coated balloon catheter sized to fit within blocked or constricted coronary arteries to treat coronary in-stent restenosis.
March 4, 2024
Artery Heart 3 D Social
AI-powered blood test supports risk stratification of heart disease patients
By Nick Paul Taylor
A blood test powered by artificial intelligence (AI) has shown promise in the assessment of patients with total blockage of a heart artery.
November 27, 2023
Heart Pulmonary Trunk Social
Elevated lipoprotein(a) predicts recurrent heart disease in seniors
By Elissa Wolfson
Elevated lipoprotein(a), a bad cholesterol variant, was found to increase the risk of recurrent coronary heart disease in senior citizens.
June 13, 2023
Heart Attack Disease 3 D Social(1)
RNA biomarkers may help confirm heart disease, study finds
By Elissa Wolfson
RNA analysis of blood from patients with angiographically confirmed coronary artery disease demonstrates how RNA biomarkers may help confirm heart disease.
March 30, 2023
Heart Attack Disease 3 D Social
Clinical-grade wearables developer Cardiosense raises $15.1M in Series A financing
By LabPulse.com staff writers
The Chicago-based digital health company is leveraging artificial intelligence and multisensor devices to develop tools that enable the early detection of cardiovascular disease.
December 8, 2022
Heart Attack Woman Social
Epigenetics testing firm Cardio Diagnostics goes public on Nasdaq
By Leo O'Connor
At the core of its cardiovascular solutions is the Integrated Genetic-Epigenetic Engine, developed at the University of Iowa.
October 26, 2022
Heart Social
Boston Heart Diagnostics launches polygenic risk map
By LabPulse.com staff writers
The risk map leverages polygenic risk scores (PRS) to provide physicians with an understanding of a patient's absolute genetic risk of complex disease, allowing for the creation of early, personalized intervention strategies, the firm said.
September 12, 2022
2019 04 17 00 53 3368 Dna Sequence 400
Polygenic score predicts risk of sudden cardiac death
By Joseph Constance
In the study, published by researchers at Cedars-Sinai Medical Center in Los Angeles and collaborators elsewhere, patients with coronary artery disease but without severely impaired heart function received the highest polygenic risk score, indicating a 77% increased risk for sudden cardiac death.
August 28, 2022
2020 06 09 23 55 3449 Heart Attack Disease 3 D 400
Study identifies risk factors for death from coronavirus
By Abraham Kim
In the observational study, Dr. Bin Cao of Capital Medical University and colleagues from China examined the data of 191 patients with confirmed COVID-19 at two different hospitals. The median age of the patients was 56 and nearly 30% died in the hospitals. They also had various comorbidities, the most common being hypertension (30% of patients), diabetes (19%), and coronary artery disease (8%).
March 10, 2020
2020 02 03 19 15 3343 Virus Coronavirus2 400
Genetic risk scoring not ready for prime time in heart disease
By Emily Hayes
One study evaluated risk scoring in a cohort of participants in UK Biobank, a nonprofit research project that is performing whole genome sequencing on a mass scale in the U.K. The observational study assessed polygenic risk scores, pooled cohort equations (risk prediction models), and both combined for predicting events in 352,660 participants with no cardiovascular disease at baseline.
February 18, 2020
2019 11 15 19 27 0360 Heart Scan 400
Should blood donations be screened for high cholesterol?
By Brian Casey
Familial hypercholesterolemia is found in 1 in 250 individuals in the general population, and it can lead to premature coronary artery disease (CAD) due to elevated levels of low-density lipoprotein (LDL) cholesterol. The condition is underdiagnosed and undertreated, although it is easily detected through blood lipid profiles or genetic testing; treatment includes statins, which effectively reduce LDL cholesterol levels.
May 22, 2019
2019 05 21 23 51 7032 Blood Cell Clot 400
Gencove scores NIH small business grant
By LabPulse.com staff writers
The amount of the grant was not disclosed.
April 25, 2019
2019 04 26 21 48 5250 Money Hundred Bills 400
Page 1 of 1